Sanofi (SNY)
| Market Cap | 103.85B -25.9% |
| Revenue (ttm) | 54.60B +4.8% |
| Net Income | 8.71B +19.9% |
| EPS | 7.15 +23.0% |
| Shares Out | 1.20B |
| PE Ratio | 11.92 |
| Forward PE | 8.64 |
| Dividend | $1.77 (4.06%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 1,320,171 |
| Open | 43.45 |
| Previous Close | 43.54 |
| Day's Range | 43.30 - 43.73 |
| 52-Week Range | 42.33 - 53.36 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 64.97 (+49.22%) |
| Earnings Date | Apr 23, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $64.97, which is an increase of 49.22% from the latest price.
News
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa
Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa
1 Dirt Cheap Growth Stock to Buy Right Now
Sanofi is generating some solid growth and it trades at an incredibly low valuation.
Sanofi reports ElevAATe trial of efdoralprin alfa meets primary endpoint
Sanofi (SNY) announced data from the global ElevAATe phase 2 study demonstrated superiority of investigational efdoralprin alfa over standard-of-care therapy in achieving and maintaining normalized fu...
Sanofi says rare lung disease drug outperforms standard care in trial
French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease.
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Sanofi's Strategic Acquisition of AgomAb Therapeutics NV Shares
Sanofi's Strategic Acquisition of AgomAb Therapeutics NV Shares
Shirley Ballas looks back: ‘I was crying about a breakup, so Mum smacked me round the face’
The Strictly judge and her mum on Shirley’s love of dance, being a single-parent family, and the joy of living together now Born in Wallasey (now Merseyside) in 1960, Shirley Ballas is one of the most...
Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports
Sanofi has asked the U.S. Food and Drug Administration to pull its diabetes drug out of the regulator's new fast-track review program, STAT News reported on Wednesday.
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization pow...
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
Novavax Q1 2026 Earnings Call Transcript
Novavax (NASDAQ: NVAX) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call t...
Regeneron, Sanofi present results from Dupixent Phase 4 trial
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the REMODEL Phase 4 trial demonstrating that Dupixent showed significant and clinically meaningful improvements in both esophag...
Sanofi invests C$294M to expand AI Center of Excellence in Toronto
Sanofi (SNY) is expanding its global Artificial Intelligence Centre of Excellence in Toronto, deepening its investment in Ontario and growing AI talent to develop and manufacture medicines and vaccine...
Sanofi downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Sanofi (SNY) to Equal Weight from Overweight with a price target of $52, down from $55. Q1 results support upside to 2026 numbers and scope for a
Ignite Solutions: What the U.S. Pharmaceutical Industry Could Learn from How Africa Solves Patient Access
A veteran of Pfizer, Sanofi, and Novo Nordisk who built patient access programmes across West Africa argues that the $500 billion medication adherence crisis plaguing American healthcare has alread...
Merck KgaA's New CEO Kai Beckmann Takes Charge As Belén Garijo Becomes Sanofi CEO
(RTTNews) - German science and technology major Merck KGaA's (MKGAY, MRK.DE) new Chief Executive Officer Kai Beckmann took charge on Friday, succeeding Belén Garijo, who joined French rival Sanofi SA ...
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on Apri...
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%
Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing p...
Sanofi Prices EUR 2.3 Bln Notes Offering Across Three Tranches
(RTTNews) - Sanofi (SNY), a biopharmaceutical company, announced that it has priced its offering of 2.3 billion Euros of notes across 3 tranches. Sanofi intends to use the net proceeds of the offering...
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery
Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.
Sanofi: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million...
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million...
Sanofi (SNY) Gains EMA's Support for Multiple Sclerosis Treatment
Sanofi (SNY) Gains EMA's Support for Multiple Sclerosis Treatment